A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

NCT01467479 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

185

Enrollment

INDUSTRY

Sponsor class

Stopped It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy endpoint as part of a decision to modify drug development plan.

Conditions

Hepatitis C

Interventions

DRUG: Telaprevir
DRUG: Ribavirin
BIOLOGICAL: Pegylated Interferon Alfa-2a
DRUG: Highly Active Antiretroviral Therapy (HAART)

Sponsor

Vertex Pharmaceuticals Incorporated